



ASX Announcement and Media Release

Tuesday 19 May 2009

SciGen Limited

SCIGEN TERMINATES DISTRIBUTION AGREEMENT FOR HUMAN INSULIN IN CHINA

The Board of Directors of SciGen Limited (ASX: SIE) (the “SciGen”) announces that the Commercialization Agreement entered into on 12 December 2003 between the SciGen and Shenzhen Medicines and Health Products Imp & Exp Co Ltd. (“SMHP”) Hefei Life Science & Technology Park Investments & Development Co Ltd (“HLST”) for the sale and distribution of SciGen’s recombinant human insulin (SciLin™) in the Peoples Republic of China was terminated by the mutual consent of both parties.

The product has been registered with the Chinese Food and Drug Administration (“SFDA”) and SciGen is currently exploring other opportunities to commercialize its recombinant human insulin in China.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in the USA, Canada, Australia, S. Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Adam Allerhand Chairman & CEO SciGen Ltd +65 6779 6638